You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

First-line Maintenance Therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Tumors Trial in Nanjing (Niraparib)

Completed
  • Ovarian Neoplasms
  • Nanjing, China
    Zhongda hospital
Feb 17, 2023

Gastric Cancer Trial (Fruquintinib+PD-1)

Not yet recruiting
  • Gastric Cancer
  • (no location specified)
Feb 1, 2023

Advanced Colorectal Carcinoma Trial in Beijing (OH2, Capecitabine, Bevacizumab)

Not yet recruiting
  • Advanced Colorectal Carcinoma
  • OH2
  • +2 more
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
Jan 28, 2023

Ovarian Cancer Trial (Huaier granule)

Not yet recruiting
  • Ovarian Cancer
  • Huaier granule
  • (no location specified)
Feb 28, 2023

HR Positive HER2 Negative Advanced Breast Cancer Trial in Tianjin (Chidamide)

Recruiting
  • HR Positive HER2 Negative Advanced Breast Cancer
  • Tianjin, China
    天津市肿瘤医院
May 26, 2023

Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer Trial in Guangzhou (Fluzoparib

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Cetntre
Sep 25, 2023

Cancer of Pancreas Trial in Cairo (Capecitabine, follow up)

Recruiting
  • Cancer of Pancreas
  • Cairo, Egypt
  • +2 more
Sep 30, 2022

Prostatic Adenocarcinoma Trial in Seoul (Enzalutamide)

Not yet recruiting
  • Prostatic Adenocarcinoma
  • Seoul, Korea, Korea, Republic of
    Samsung Medical Center
Aug 23, 2023

First-line Olaparib Combined With Bevacizumab Maintenance

Not yet recruiting
  • Ovarian Neoplasms
  • olaparib plus bevacizumab maintenance therapy
  • (no location specified)
Jun 29, 2022

Metastatic Colorectal Cancer Trial in Guangzhou (Fruquintinib alternating with Bevacizumab plus Capecitabine, Bevacizumab plus

Recruiting
  • Metastatic Colorectal Cancer
  • Fruquintinib alternating with Bevacizumab plus Capecitabine
  • Bevacizumab plus Capecitabine
  • Guangzhou, Guangdong, China
    Nanfang Hospital, Southern Medical University
Jan 4, 2023

Ovarian Cancer Trial in Guangzhou (Pamiparib/Tamoxifen)

Not yet recruiting
  • Ovarian Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Centre
Dec 30, 2022

Limited Stage Small Cell Lung Cancer, Not Progressed After First-line Chemoradiotherapy Trial in Jinan (TQB2450 Injection +

Recruiting
  • Limited Stage Small Cell Lung Cancer
  • Not Progressed After First-line Chemoradiotherapy
  • TQB2450 Injection + Anlotinib Hydrochloride Capsules
  • Jinan, Shandong, China
    Cancer Hospital Affiliated to Shandong First Medical University
Jul 5, 2023

Metastatic Nasopharyngeal Carcinoma Trial (Capecitabine plus toripalimab)

Not yet recruiting
  • Metastatic Nasopharyngeal Carcinoma
  • Capecitabine plus toripalimab
  • (no location specified)
Jul 30, 2022

Metastatic Breast Cancer Trial (Inavolisib, Phesgo, Placebo)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Jun 7, 2023

Locally Advanced Head and Neck Squamous Cell Carcinoma Trial (Toripalimab)

Not yet recruiting
  • Locally Advanced Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Mar 20, 2023

Colorectal Cancer, Colorectal Cancer Stage IV Trial (Fruquintinib Plus Capecitabine, Capecitabine)

Not yet recruiting
  • Colorectal Cancer
  • Colorectal Cancer Stage IV
  • (no location specified)
Jul 9, 2022

Colorectal Cancer Trial in Hangzhou (Fruquintinib Plus Capecitabine, Bevacizumab Plus Capecitabine)

Recruiting
  • Colorectal Cancer
  • Fruquintinib Plus Capecitabine
  • Bevacizumab Plus Capecitabine
  • Hangzhou, Zhejiang, China
    the Second Affiliated Hospital of Medical College of Zhejiang Un
Jul 25, 2022

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial (3 cycles chemo instead of 6 cycles chemo, 6 cycles

Not yet recruiting
  • Ovarian Cancer
  • +3 more
  • 3 cycles chemotherapy instead of 6 cycles chemotherapy
  • 6 cycles chemotherapy
  • (no location specified)
Jul 12, 2022

First-line Olaparib Mono-maintenancerapy-a Multicenter,

Not yet recruiting
  • Ovarian Neoplasms
  • Olaparib mono-maintenance therapy
  • (no location specified)
Dec 8, 2021

NSCLC Trial in Ostrava (primary tumour radiotherapy, stereotactic body radiotherapy, maintenance radiotherapy)

Recruiting
  • Non-small Cell Lung Cancer
  • primary tumour radiotherapy
  • +2 more
  • Ostrava, Moravian-Silesian Region, Czechia
    University Hospital Ostrava
Dec 6, 2022

Non Small Cell Lung Cancer Trial in Ostrava (Chemotherapy, Radiotherapy (RT) + Stereotactic Body Ratio Therapy (SBRT),

Recruiting
  • Non Small Cell Lung Cancer
  • Chemotherapy
  • +2 more
  • Ostrava, Moravian-Silesian Region, Czechia
    University Hospital Ostrava
Dec 19, 2022

SOGUG-AVELUMAB_RWD

Recruiting
  • Metastatic Urothelial Carcinoma
  • Vigo, Pontevedra, Spain
  • +21 more
Jan 17, 2023

Chronic Lymphocytic Leukemia Trial in Cologne (lenalidomide, Placebo)

Completed
  • Chronic Lymphocytic Leukemia
  • Cologne, Germany
  • +1 more
Dec 16, 2021

Lung Cancer Trial in Tianjin (PD-1 inhibitor, PARP inhibitor)

Recruiting
  • Lung Cancer
  • PD-1 inhibitor
  • PARP inhibitor
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
May 23, 2022

Colo-rectal Cancer Trial in Shanghai (Fruquintinib)

Recruiting
  • Colo-rectal Cancer
  • Shanghai, Shanghai, China
    Zhongshan Hospital Affiliated to Fudan University
Nov 1, 2021